|Day Low/High||2.00 / 2.07|
|52 Wk Low/High||0.73 / 2.75|
Investors in Novavax, Inc. saw new options become available this week, for the October 19th expiration.
Investors in Novavax, Inc. saw new options become available this week, for the March 16th expiration.
In trading on Wednesday, shares of Novavax, Inc. touched a new 52-week high of $1.98/share.
Novel vaccine candidate, NanoFlu™, outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study
Novavax, Medicines Co. and Biogen were among the biotech stock movers in premarket trading on July 25.
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.
- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults
The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 7,426,054 share decrease in total short interest for Novavax, Inc. , to 56,851,825, a decrease of 11.55% since 06/15/2017.
Alexion, Arena and Novavax were among the biotech stock movers ahead of the market open on Friday, July 7.
Pacific Biosciences of California, AveXis and Novavax were among the biotech stock movers in premarket trading on Thursday.
Investors are in full wait and see mode.
Stocks wade further into the green on Wednesday afternoon after former FBI director James Comey's prepared testimony is made public.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.